Replimune Group’s experimental combination therapy for skin cancer, involving its lead therapy RP1 and Regeneron’s Libtayo, failed to significantly remove cancerous lesions in a mid-stage study. However, the company stated that the rate of complete disappearance of tumors was just short of statistical significance. The study focused on improvements in complete response rate (CRR) and overall response rate (ORR). Replimune will continue the trial as planned under its agreement with Regeneron.
Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News